Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 3/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515938 | 0.76 | GRM4 (0.31) | — | |
| SCHEMBL1594947 | 0.76 | MAPT (0.38) | — | |
| SCHEMBL195199 | 0.72 | MAPT (0.39) | PIK3CB | |
| Isoquinolin-3-Amine SCHEMBL29975748 | 0.72 | PDPK1 (1.00) | PDPK1PIK3CBNOS3NOS2NOS1 | |
| Isoquinolin-3-Amine SCHEMBL30378027 | 0.72 | PDPK1 (1.00) | PDPK1PIK3CBNOS3NOS2NOS1 | |
| Isoquinolin-3-Amine SCHEMBL177520 | 0.72 | PDPK1 (1.00) | PDPK1PIK3CBNOS3NOS2NOS1 | |
| SCHEMBL70257 | 0.70 | — | — | |
| SCHEMBL559813 | 0.70 | — | — | |
| SCHEMBL4765233 | 0.70 | PDPK1 (0.64) | PDPK1PIK3CBNOS3NOS2NOS1 | |
| Isoquinolin-3-Amine SCHEMBL28187424 | 0.70 | PDPK1 (0.95) | PDPK1PIK3CBNOS3NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | claimed |
| EP-2892892-B1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | claimed |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | claimed |
| EP-2892892-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR!THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2015-07-15 | — | — | EP | claimed |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, NV (BE) | 2015-04-09 | — | — | US | claimed |
| WO-2014039769-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-13 | — | — | WO | claimed |
| EP-1981884-B1 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | AMGEN INC (US) | 2012-06-13 | — | — | EP | claimed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | claimed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | claimed |
| EP-1981884-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | Amgen, Inc (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | claimed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | claimed |
| CN-117209469-A | Compounds as CLK inhibitors and uses thereof | 南京圣和药物研发有限公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-3752492-B1 | FUNGICIDAL OXADIAZOLES | BAYER AG (DE) | 2022-12-21 | — | — | EP | disclosed |
| US-20210009541-A1 | FUNGICIDAL OXADIAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-14 | — | — | US | disclosed |
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-6710058-B2 | USE AS ANTICOAGULANT AGENTS FOR THERAPY AND PROPHYLAXIS OFTHROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-23 | — | — | US | disclosed |
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | PDPK1 249/4885PIK3CB 1500/4885NOS3 113/4885 |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | PDPK1 249/4885PIK3CB 1500/4885NOS3 113/4885 |
| US-20210009541-A1 | FUNGICIDAL OXADIAZOLES | OXA1L, CYP51A1, CYP4X1 | PDPK1 1568/4885PIK3CB 1452/4885NOS3 149/4885 |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | PDPK1 249/4885PIK3CB 1500/4885NOS3 113/4885 |
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | PDPK1 2419/4885PIK3CB 2799/4885NOS3 4042/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | PDPK1 70/4885PIK3CB 536/4885NOS3 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.